- Home
- MNPR vs AGNT Comparison
MNPR vs AGNT Comparison
Compare MNPR & AGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNPR | AGNT |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.4M | 621.7M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | MNPR | AGNT |
|---|---|---|
| Price | $71.87 | $2.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $129.92 | $6.00 |
| AVG Volume (30 Days) | 115.3K | ★ 1.5M |
| Earning Date | 11-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 6.22% |
| EPS Growth | ★ 54.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $500,147,681.00 |
| Revenue This Year | N/A | $3.76 |
| Revenue Next Year | N/A | $7.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 220.39 |
| 52 Week Low | $50.07 | $2.98 |
| 52 Week High | $124.82 | $5.79 |
Technical Indicators
Market Signals| Indicator | MNPR | AGNT |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 35.00 |
| Support Level | $66.88 | N/A |
| Resistance Level | $75.20 | $4.15 |
| Average True Range (ATR) | 4.05 | 0.30 |
| MACD | 1.22 | -0.11 |
| Stochastic Oscillator | 71.74 | 0.35 |
Price Performance
Historical ComparisonAbout MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
About AGNT AGNT Inc. Common Stock
AGNT Inc is a multi-model real estate platform, with brands including eXp Realty, eXp Commercial, NextHome, FrameVR.io, and SUCCESS Enterprises. The group prioritizes transparency, innovation, and long-term value for agents, franchise owners, staff, and shareholders.